13 June 2013Patents

US Supreme Court strikes Myriad blow

The US Supreme Court has ruled that isolated human DNA is not patent eligible and has struck down patents owned by biotech company Myriad, ending a long-running and controversial case.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Patents

ACLU files Supreme Court brief in Myriad case

29 January 2013 The American Civil Liberties Union (ACLU) has urged the US Supreme Court to invalidate Myriad Genetics’ patent claims over two human genes linked to breast and ovarian cancer.

Patents

Myriad: Keeping a low profile

1 December 2012 The latest rulings in the controversial legal battle over breast cancer gene patents seem to have found two out of three issues in defendant Myriad Genetics’ favour, but legal counsel Ben Jackson isn’t too excited by the implications.

Patents

Myriad decision applied in diagnostic claims case

6 November 2013 The US District Court for the Northern District of California has found that diagnostic claims covering conventional detection methods do not make the use of a natural phenomenon patent eligible.

On our radar...

Philip Morris case triggers AIPPI call for EPO action

Penn State prevails in trademark dispute with Vintage Brand over retro logos

Google: Ex-engineer ‘touted dominion over the trade secrets he stole’

‘Trade secrets can be emotional’: Seth Gerber, Morgan Lewis

Private equity eyes controlling interest in Anaqua

Motorola can’t enforce ‘multiple’ US Hytera damages in UK

UK firms Venner Shipley and AA Thornton combine

US Supreme Court strikes Myriad blow

More on this story

Editor's picks

Editor's picks

More articles